Anti-CD19 CAR T cells for refractory myasthenia gravis
- PMID: 37977704
- DOI: 10.1016/S1474-4422(23)00375-7
Anti-CD19 CAR T cells for refractory myasthenia gravis
Conflict of interest statement
DB is an employee and shareholder of Kyverna Therapeutics. GS has received consulting fees from Kyverna Therapeutics and Cabaletta. All other authors declare no competing interests. AH and TH contributed equally. DM provided the pivotal conceptual framework of the study. AH and DM have verified the data presented; all authors had full access to all the data analysed in the case report and accept responsibility for submitting this Correspondence for publication. The study was supported by the Deutsche Forschungsgemeinschaft (FOR2886, RTG2408, TRR221, CRC1181).
Similar articles
-
Are CAR T cells the answer to myasthenia gravis therapy?Lancet Neurol. 2023 Jul;22(7):545-546. doi: 10.1016/S1474-4422(23)00211-9. Lancet Neurol. 2023. PMID: 37353270 No abstract available.
-
[Problems posed by the use of anti-thymocyte globulins in myasthenia (apropos of the treatment of 2 cases of myasthenia gravis)].Mars Med. 1972;109(6):395-407. Mars Med. 1972. PMID: 4538918 French. No abstract available.
-
Myasthenia gravis, thymectomy and T-cells.Neurology. 1979 Mar;29(3):419. doi: 10.1212/wnl.29.3.419. Neurology. 1979. PMID: 313026 No abstract available.
-
Strategies for treatment of myasthenia gravis.Ann N Y Acad Sci. 1993 Jun 21;681:515-28. doi: 10.1111/j.1749-6632.1993.tb22935.x. Ann N Y Acad Sci. 1993. PMID: 8357193 Review. No abstract available.
-
Vaccines against myasthenia gravis.Expert Opin Biol Ther. 2005 Jul;5(7):983-95. doi: 10.1517/14712598.5.7.983. Expert Opin Biol Ther. 2005. PMID: 16018742 Free PMC article. Review.
Cited by
-
Advancements and challenges in CAR T cell therapy in autoimmune diseases.Nat Rev Rheumatol. 2024 Sep;20(9):531-544. doi: 10.1038/s41584-024-01139-z. Epub 2024 Aug 6. Nat Rev Rheumatol. 2024. PMID: 39107407 Review.
-
[CAR T cells in non-malignant diseases].Inn Med (Heidelb). 2025 Aug;66(8):810-817. doi: 10.1007/s00108-025-01945-x. Epub 2025 Jun 30. Inn Med (Heidelb). 2025. PMID: 40586812 Review. German.
-
CAR-engineered T cell therapy as an emerging strategy for treating autoimmune diseases.Front Med (Lausanne). 2024 Oct 10;11:1447147. doi: 10.3389/fmed.2024.1447147. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39450112 Free PMC article. Review.
-
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making.BioDrugs. 2025 Mar;39(2):185-213. doi: 10.1007/s40259-024-00701-1. Epub 2025 Jan 27. BioDrugs. 2025. PMID: 39869260 Free PMC article. Review.
-
Tonic signaling in CAR-T therapy: the lever long enough to move the planet.Front Med. 2025 Jun;19(3):391-408. doi: 10.1007/s11684-025-1130-x. Epub 2025 Mar 21. Front Med. 2025. PMID: 40117019 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical